SCHEMBL20656381

SCHEMBL20656381

O=S(=O)(Cl)c1cnc(Cl)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.38
NPSR1 Q6W5P4 4/20 0.38
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
APLNR P35414 1/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 2/20 0.33
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
PIK3CD O00329 2/20 0.31
PIK3CA P42336 1/20 0.31
PIK3CB P42338 1/20 0.31
PIK3CG P48736 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18668405 0.82 CA2 (0.50) ALDH1A1NPSR1CA1CA2CA9
SCHEMBL20401438 0.82 ALDH1A1 (0.38) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL20656519 0.80 ALDH1A1 (0.37) ALDH1A1HSD17B10TDP1CA1CA2
SCHEMBL31018073 0.79 ALDH1A1 (0.56) ALDH1A1NPSR1HSD17B10TDP1CA1
SCHEMBL958949 0.79 ALDH1A1 (0.56) ALDH1A1NPSR1HSD17B10TDP1CA1
SCHEMBL1156197 0.76 ALDH1A1 (0.41) ALDH1A1NPSR1HSD17B10TDP1MAPT
SCHEMBL21773307 0.76 ALDH1A1 (0.38) ALDH1A1NPSR1HSD17B10TDP1CA1
SCHEMBL30456616 0.76 ALDH1A1 (0.41) ALDH1A1NPSR1HSD17B10TDP1MAPT
SCHEMBL516599 0.76 ALDH1A1 (0.57) ALDH1A1NPSR1MAPTGAALMNA
SCHEMBL1278519 0.76 PIK3CD (0.44) ALDH1A1NPSR1HSD17B10TDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115745910-B Chemical compound 安塔比奥公司 2025-05-27 CN disclosed
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-10 US disclosed
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors GENENTECH, INC. (US) 2025-01-28 US disclosed
EP-3655405-B1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2023-06-07 EP disclosed
EP-3655405-B1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2023-06-07 EP disclosed
CN-115745910-A Chemical compound 安塔比奥公司 2023-03-07 CN disclosed
CN-110446708-B Chemical compound 安塔比奥公司 2022-12-02 CN disclosed
US-20220315546-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2022-10-06 US disclosed
US-11299467-B2 Chemical compounds ANTABIO SAS (FR) 2022-04-12 US disclosed
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2021-07-15 US disclosed
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2021-07-15 US disclosed
EP-3797101-A1 PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-03-31 EP disclosed
CN-112368274-A Pyridine-sulfonamide derivatives as sodium channel inhibitors 豪夫迈·罗氏有限公司 2021-02-12 CN disclosed
US-20200339526-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2020-10-29 US disclosed
US-20200339526-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2020-10-29 US disclosed
EP-3655405-A1 CHEMICAL COMPOUNDS Antabio SAS (FR) 2020-05-27 EP disclosed
WO-2019016393-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2019-01-24 WO disclosed
EP-3431474-A1 CHEMICAL COMPOUNDS Antabio SAS (FR) 2019-01-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315546-A1 CHEMICAL COMPOUNDS MRPL21, MLX, TXN ALDH1A1 1565/4885NPSR1 498/4885HSD17B10 3379/4885
US-11299467-B2 Chemical compounds MRPL21, MLX, CFTR ALDH1A1 1225/4885NPSR1 486/4885HSD17B10 3240/4885
US-20200339526-A1 CHEMICAL COMPOUNDS MRPL21, MLX, CFTR ALDH1A1 1225/4885NPSR1 486/4885HSD17B10 3240/4885
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors SCN1B, CACNA1A, SCN1A ALDH1A1 3192/4885NPSR1 151/4885HSD17B10 4306/4885
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS SCN1B, CACNA1A, SCN1A ALDH1A1 3086/4885NPSR1 158/4885HSD17B10 4292/4885
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF F12, REN, ZYX ALDH1A1 2171/4885NPSR1 125/4885HSD17B10 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.